TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04751604

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: Daily oral administration of 1,000 mg nicotinamide \[1x 500-mg conventional nicotinamide tablet and 1x 500-mg tablet with controlled-ileocolonic-release nicotinamide (CICR-NAM)\] for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral administration of 2 matching placebo tablets for 4 weeks
Study: NCT05984407

Intervention type: PROCEDURE
Intervention: cytokine hemadsorption therapy
Description: Observation of cytokine hemadsorption therapy in critically ill patients who have no microbiological findings and develop vasoplegic shock.
Study: NCT06086158

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nordic Reverse Protocol
Description: The participant begins on their knees, with the trunk upright and fully aligned. At this moment, the soccer player slowly leans back, maintaining the starting position by means of a controlled flexion of the knees. This fall is executed at the lowest speed possible to maximize muscle load in the eccentric phase and reach the point of maximum flexion.
Study: NCT05327842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New training simulator
Description: Participants receive training with new simulator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional simulator
Description: Participants receive traditional training
Study: NCT04880083

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Commercially Available Starter Infant Formula
Description: Study formula is provided in powder form and will be administered orally, ad libitum, via an infant feeding bottle and the volume of formula offered to the infant will be guided by the recommended feeding table for the age group or by physician recommendation. The amount consumed by the infant will vary by each infant's weight and appetite.
Study: NCT05135585

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample collection
Description: Blood sample collection at 1 month and 6 months after vaccination

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: data collection (health data, vaccination data, etc.)
Study: NCT06203457

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod
Description: Patients receiving efgartigimod infusions
Study: NCT05436535

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Adult dupilumab-naïve topical steroid non-responder (EASI \>7) participants beginning treatment with dupilumab will initially receive a loading dose of two 300 mg subcutaneous injections. The two injections will be administered at different sites in the abdomen, thighs, or upper arms. Pediatric dupilumab-naïve topical steroid non-responder participants beginning treatment with dupilumab will receive a loading dose, according to their weight. Dupilumab-naïve topical steroid non-responsive participants will continue use of dupilumab on a schedule determined by their age and weight until their penultimate scheduled visit (Day 140-196).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vanicream- Dupilumab-naïve
Description: Dupilumab-naïve AD participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at their penultimate visit (Day 140-196) through the End of Study Assessment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: On Day 7, all dupilumab-naïve AD participants will begin applying triamcinolone 0.1% ointment (provided by the study) twice daily to the specified target area. Additionally, dupilumab-naïve AD participants will apply triamcinolone 0.1% ointment twice daily to active lesions on non-sensitive, non-target skin.~Between Day 35 and Day 140, dupilumab-naïve AD topical steroid responsive (EASI ≤ 7) participants will apply triamcinolone 0.1% ointment (provided by the study) once or twice daily, per clinician discretion, to the specified target area. Additionally, participants will apply triamcinolone 0.1% ointment once or twice daily, per clinician discretion, to active lesions on non-sensitive skin body wide.~Between Day 35 and Day 140, dupilumab-naïve topical steroid non-responder (EASI \>7) participants may apply triamcinolone 0.1% ointment as needed to active lesions on non-sensitive, non-target skin.
Study: NCT05725967

Intervention type: DEVICE
Intervention: Argon Plasma Coagulation, Gastroplasty with Endoscopic Myotomy, Bariatric Endoscopic Antral Myotomy, Pylorus Sparing Antral Myotomy
Description: Electrosurgical interventions for obesity. Use of electrosurgical devices, such as electrocautery for the primary treatment of obesity or obesity related complications.

Intervention type: DEVICE
Intervention: Argon Plasma Coagulation, Gastroplasty with Endoscopic Myotomy, Bariatric Endoscopic Antral Myotomy, Pylorus Sparing Antral Myotomy
Description: Electrosurgical interventions for obesity. Use of electrosurgical devices, such as electrocautery for the primary treatment of obesity or obesity related complications.

Intervention type: DEVICE
Intervention: Aspiration Therapy
Description: Placement of an aspiration therapy device for the treatment of obesity.
Study: NCT05436535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: On Day 7, all dupilumab-naïve AD participants will apply hydrocortisone 2.5% ointment twice daily to active lesions on sensitive, non-target skin.~Between Day 35 and Day 140, dupilumab-naïve AD topical steroid responsive (EASI ≤ 7) participants will apply hydrocortisone 2.5% ointment once or twice daily, per clinician discretion, to active lesions on sensitive skin body wide.~Between Day 35 and Day 140, dupilumab-naïve topical steroid non-responder (EASI \>7) participants may apply hydrocortisone 2.5% ointment as needed to active lesions on sensitive, non-target skin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vanicream- Active
Description: Non-AD control participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at Day 140 through the End of Study Assessment Visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vanicream- Experienced Dupilumab
Description: Long-term dupilumab participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at Day 140 through the End of Study Assessment Visit.
Study: NCT05348993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G03-52-01
Description: G03-52-01 administered intramuscularly

Intervention type: DRUG
Group type: OTHER
Intervention: G03-52-01
Description: G03-52-01 administered intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G03-52-01
Description: G03-52-01 administered intramuscularly

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT05898672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Single oral dose of rosuvastatin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Single oral dose of rosuvastatin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir
Description: Twice daily oral doses of nirmatrelvir/ritonavir tablets
Study: NCT04984083

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin k
Description: patients will take vitamin k 10 mg/ml once daily orally or IM between four and 96 hours before elective cesarean section
Study: NCT06013670

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy+NSBBs
Description: Endoscopic treatment+NSBBs group: After admission, carvedilol 6.25mg qd p.o. was administered to lower portal vein pressure. After one week without any adverse reactions, add the dosage to 12.5mg qd, maintained for a long time, with close monitoring of blood pressure and pulse (morning and evening monitoring) during dosing and later use, to maintain systolic blood pressure\>90mmHg and heart rate\>55bpm. Otherwise, dosage reduction or even discontinuation of medication is necessary. Endoscopic treatment adopts sequential treatment, with an interval of four weeks, until the varicose vein becomes mild or disappears.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt
Description: TIPS group: All TIPS procedures are completed by a professional liver disease intervention treatment team.
Study: NCT05490329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tough Talks COVID
Description: Intervention participants will download the TT-C app from the iOS or Google Play store and complete the intervention within one month.
Study: NCT04984720

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone based digital application
Description: Smartphone Based Digital Application to Track Migraine, Offer Pill Reminders for Medication Adherence and Community Blog

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone based digital application
Description: Smartphone Based Digital Application to Track Migraine, Offer Pill Reminders for Medication Adherence and Community Blog
Study: NCT05209984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADF1 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 75mg
Description: Participant will receive for two (2) weeks one (01) ADF sibutramine IR/topiramate XR 5mg/25mg placebo capsule once daily + one (01) sibutramine placebo capsule 10mg; after that 2 weeks, participants will receive one (01) placebo capsule of ADF sibutramine IR/ topiramate XR 5mg/25mg once daily + one (01) capsule of ADF sibutramine IR/ topiramate XR 5mg/25mg once daily + one (01) 10mg sibutramine placebo capsule; after this period, they will receive two (02) capsules of ADF sibutramine IR/topiramate XR 5mg/25mg (totaling 10mg of sibutramine and 50mg of topiramate) + a placebo capsule of ADF sibutramine IR/topiramate XR 5mg/25mg once a day + one (one) 10mg sibutramine placebo capsule, taken once daily, for two (02) additional weeks, on the titration scheme. On the treatment period, will receive one (01) ADF Sibutramine IR/Topiramate XR 15mg/75mg capsule + one (01) Sibutramine IR 15mg placebo capsule (Sibus®) + one (01) Topiramate XR 100mg placebo capsule, once daily, for 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADF2 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 100mg
Description: Participant will receive for two (02) weeks one (01) capsule of ADF sibutramine IR/topiramate XR 5mg/25mg once daily + one (01) capsule of placebo sibutramine 10mg; after this initial period of 2 weeks, participants will receive (02) ADF sibutramine IR/topiramate XR 5mg/25mg capsules (totaling 10mg of sibutramine and 50mg of topiramate) + one (01) 10mg sibutramine placebo capsule, taken once daily, for two (02) weeks; after this period, they will receive three (03) capsules of ADF sibutramine IR/topiramate XR 5mg/25mg (totaling 15mg of sibutramine and 75mg of topiramate) + one (01) capsule of 10mg sibutramine placebo, taken once daily, for two ( 02) additional weeks, on titration scheme. On the treatment period, will receive one (01) Sibutramine IR 15mg capsule (Sibus®) + one (01) Topiramate XR 100mg capsule + one (01) ADF placebo capsule sibutramine IR/topiramate XR 15mg/75mg, taken once daily, taken once daily, for 52 weeks.
Study: NCT04933045

Intervention type: DEVICE
Intervention: Arthrex InternalBrace
Description: Placement of Arthrex InternalBrace for anatomic distal tibiofibular ligament augmentation to stabilize the ankle syndesmosis during surgery.
Study: NCT05121259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ExerciseGuide Intervention Group
Description: The single group which will be given access to the eight-week ExerciseGuide UK website containing a tailored physical activity programme and supportive and educational resources.
Study: NCT05927220

Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsy Specimens Histopathology
Description: paraffin-embedded blocks with sections from the tumor will be selected. Patterns of invasion will be recorded by for all cases by histopathologists

Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsy Specimens Histopathology
Description: paraffin-embedded blocks with sections from the tumor will be selected. Patterns of invasion will be recorded by for all cases by histopathologists
Study: NCT04838860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Siltuximab
Description: Participants will receive intravenous (IV) infusion of siltuximab 22 mg/kg over 2 hours every 3 weeks, then possibly dose escalating to 33 mg/kg IV over 3 hours +/- 44 mg/kg IV over 4 hours every 3 weeks if clinically indicated in the absence of dose-limiting toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Siltuximab
Description: Participants will receive intravenous (IV) infusion of siltuximab 22 mg/kg over 2 hours every 3 weeks, then possibly dose escalating to 33 mg/kg IV over 3 hours +/- 44 mg/kg IV over 4 hours every 3 weeks if clinically indicated in the absence of dose-limiting toxicity.
Study: NCT06505954

Intervention type: OTHER
Intervention: Survey study
Description: Survey study among medical students about lower urinary tract symptoms
Study: NCT04788524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Task Manipulation
Description: Participants will complete computer tasks.
Study: NCT05209984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SIB Group Sibus (Sibutramine) 15mg
Description: Participant will receive for two (02) weeks one (01) 10mg sibutramine placebo capsule + one (01) 5mg/25mg sibutramine ADF placebo capsule IR/topiramate XR; after this initial period, they will receive for two (02) weeks one (01) 10mg sibutramine capsule + two (02) placebo capsules of ADF sibutramine IR/topiramate XR 5mg/25mg; after this 4-week period, participants will receive one (01) 10mg sibutramine capsule and three (03) ADF sibutramine IR/topiramate XR 5mg/25mg placebo capsules, taken once daily, for two (02) additional weeks. This corresponds to the titration scheme.On the treatment period, patient will receive one (01) Sibutramine 15mg capsule + one (01) Sibutramine IR/topiramate XR 15mg/75mg placebo capsule + one (01) placebo capsule of Topiramate XR 100mg, taken once daily, for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: participants randomized to the Placebo Group will receive for two (02) weeks one (01) 10mg sibutramine placebo capsule + one (01) sibutramine IR/ topiramate XR 5mg/25mg placebo capsule; after this initial period, they will receive one (01) sibutramine 10mg placebo capsule + two (02) sibutramine IR/ topiramate XR 5mg/25mg placebo capsules, taken once daily, for two (02) weeks; after this 4-week period, participants will receive one (01) 10mg sibutramine placebo capsule + three (03) ADF placebo capsules, taken once daily, for two (02) weeks.On the treatment period, patient will receive one (01) Sibutramine 15mg placebo capsule + one (01) ADF sibutramine IR/Topiramate XR 15mg/75mg placebo capsule + one (01) Topiramate XR 100mg placebo capsule, in once daily intake for 52 weeks.
Study: NCT05666999

Intervention type: DEVICE
Group type: OTHER
Intervention: FibDex®
Description: To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suprathel
Description: To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel Foam
Description: To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
Study: NCT05212298

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: The gel contains a mixture of glucose and maltodextrin
Description: The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Herbal compound low-dose
Description: The total amount of herbal compound capsules is 557 mg.
Study: NCT05279924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylaxis with Emicizumab
Description: Prophylaxis with Emicizumab in Ivoirian boys with severe hemophilia A
Study: NCT04992208

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
Study: NCT05212298

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Herbal compound high-dose
Description: The total amount of herbal compound capsules is 1114 mg.
Study: NCT06592261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia)
Description: Insulin infusion to recapitulate euinsulinemia (normal basal insulin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia)
Description: Insulin infusion to recapitulate euinsulinemia (normal basal insulin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia)
Description: Insulin infusion to recapitulate euinsulinemia (normal basal insulin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin regular, 32 mU/m2/min (hyperinsulinemia)
Description: Insulin infusion to induce hyperinsulinemia for assessment of insulin sensitivity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin regular, 32 mU/m2/min (hyperinsulinemia)
Description: Insulin infusion to induce hyperinsulinemia for assessment of insulin sensitivity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin regular, 32 mU/m2/min (hyperinsulinemia)
Description: Insulin infusion to induce hyperinsulinemia for assessment of insulin sensitivity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Acetate, 6-45 ng/kg/min
Description: Suppression of endogenous insulin secretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Acetate, 6-45 ng/kg/min
Description: Suppression of endogenous insulin secretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Acetate, 6-45 ng/kg/min
Description: Suppression of endogenous insulin secretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 20 % in Water
Description: Production of steady-state plasma glucose (SSPG) reflective of insulin sensitivity at hyperinsulinemia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 20 % in Water
Description: Production of steady-state plasma glucose (SSPG) reflective of insulin sensitivity at hyperinsulinemia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 20 % in Water
Description: Production of steady-state plasma glucose (SSPG) reflective of insulin sensitivity at hyperinsulinemia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon, 0-0.5 ng/kg/min
Description: Replacement of endogenous glucagon suppressed by octreotide. (Use is optional at the PI's discretion.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon, 0-0.5 ng/kg/min
Description: Replacement of endogenous glucagon suppressed by octreotide. (Use is optional at the PI's discretion.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon, 0-0.5 ng/kg/min
Description: Replacement of endogenous glucagon suppressed by octreotide. (Use is optional at the PI's discretion.)
Study: NCT05237791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: magnesium sulphate 50mg/kg (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline 100ml (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)
Study: NCT05138497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HILIT
Description: A total of 92 men and women 65 years old, distributed in an experimental group that will receive a 12-week of HILIT program (n = 46); and a control group (n = 46) that will only receive general recommendations on the benefits of physical exercise. The variables will be measured for both groups with the same validated tools and the same researcher to avoid information biases and differential incorrect classification.
Study: NCT06040125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Circuit Training
Description: 16-week, multicomponent exercise intervention comprised of sessions supervised by certified exercise oncology trainer and home-based, self-directed aerobic exercises. Stationary bike and accelerometer (activity/heart rate monitor) will be provided.
Study: NCT05686746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 MG
Description: 4 mg oral daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 MG
Description: 2 mg oral daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF
Description: 1000 mg oral daily
Study: NCT06139432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: * Anode opposite the left dorsolateral prefrontal cortex (between F3 and FP1 according to the 10-20 international placement system).~* Cathode opposite the left temporoparietal junction (between T3 and P3).~* The stimulation level is 2mA for 20 minutes.~* Sessions are held twice daily on working days (with a minimum of 3 hours between sessions).~Twenty sessions will be carried out, two sessions per consecutive working day.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: * Anode opposite the left dorsolateral prefrontal cortex (between F3 and FP1 according to the 10-20 international placement system).~* Cathode opposite the left temporoparietal junction (between T3 and P3).~* Effective stimulation is delivered for 30 seconds (stimulation level is 2 mA), after which effective stimulation stops. The entire session is 20 minutes, with 19 minutes and 30 seconds without stimulation.~* Sessions are held twice daily on working days (with a minimum of 3 hours between sessions).~Twenty sessions will be carried out, two sessions per consecutive working day.